Fig. 2
A p190A expression is decreased in high-invasive BC and correlates with poor prognosis. (A) Representative immunohistochemical (IHC) images of p190A in non-tumor urothelial tissue and a tissue microarray of bladder cancer (BC) samples with different pathological stages. Scale bar, 200 μm. (B, C) Statistics of IHC scores of p190A in non-muscle invasive bladder cancer (NMIBC) (pTa + pT1) and MIBC (pT2 + pT3 + pT4) patients from tissue microarrays. Statistics of IHC scores of p190A in MIBC patients with/without lymph node metastasis (D) and with/without relapse (E) from tissue microarrays. Kaplan–Meier survival curves of overall survival (F) and recurrence free survival (G) based on p190A expression in the MIBC patients. Evaluation of p190A immunoreactive (IRS) scores is calculated by the product defined by staining intensity scores x and the number of the positive cells scores as described in the Supplementary Tables 2 and 3. Based on the average p190A score across all patient samples, we set an IHC staining score of 4 as cutoff, classifying expression levels as high (≥ 4) and low (< 4). Please note that 111 out of the 152 patients with MIBC were included for the survival analyses. Patients classified as having secondary bladder cancer, as these likely represent non-initial diagnoses, including possible recurrences, second primary tumors, or cases with prior cancer history were excluded for the survival analyses to ensure consistency and avoid potential bias in survival outcomes. Statistical data are presented as mean ± SD. ANOVA (B), Student’s t-test (C); F test (D and E) and Gehan-Breslow-Wilcoxon test; (F and G) were applied for statistical analyses. ns, not statistically significant. (*p < 0.05, **p < 0.01).
